 Ariel Berlinski
Concepts (176)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Albuterol | 26 | 2024 | 56 | 11.370 |
Why?
| | Bronchodilator Agents | 29 | 2024 | 75 | 11.180 |
Why?
| | Nebulizers and Vaporizers | 30 | 2023 | 55 | 10.440 |
Why?
| | Drug Delivery Systems | 20 | 2024 | 144 | 8.450 |
Why?
| | Aerosols | 32 | 2023 | 74 | 7.020 |
Why?
| | Administration, Inhalation | 29 | 2024 | 111 | 4.650 |
Why?
| | Metered Dose Inhalers | 9 | 2024 | 17 | 3.960 |
Why?
| | Tracheostomy | 7 | 2023 | 71 | 3.130 |
Why?
| | Respiration, Artificial | 8 | 2023 | 290 | 3.110 |
Why?
| | Equipment Design | 23 | 2024 | 290 | 2.810 |
Why?
| | Asthma | 8 | 2023 | 282 | 2.600 |
Why?
| | Masks | 7 | 2016 | 30 | 2.440 |
Why?
| | Cystic Fibrosis | 8 | 2022 | 151 | 2.110 |
Why?
| | Respiratory Therapy | 6 | 2023 | 34 | 2.030 |
Why?
| | Child | 30 | 2024 | 6862 | 1.600 |
Why?
| | Spirometry | 3 | 2023 | 30 | 1.520 |
Why?
| | Lung | 7 | 2023 | 507 | 1.480 |
Why?
| | Particle Size | 9 | 2021 | 79 | 1.480 |
Why?
| | Tidal Volume | 7 | 2024 | 60 | 1.290 |
Why?
| | High-Frequency Ventilation | 3 | 2023 | 24 | 1.250 |
Why?
| | Ventilators, Mechanical | 5 | 2024 | 44 | 1.220 |
Why?
| | Humans | 57 | 2024 | 50201 | 1.200 |
Why?
| | Forced Expiratory Volume | 2 | 2020 | 44 | 1.160 |
Why?
| | Home Care Services | 2 | 2020 | 72 | 1.120 |
Why?
| | Laryngeal Masks | 1 | 2024 | 8 | 0.960 |
Why?
| | Allied Health Personnel | 1 | 2023 | 25 | 0.860 |
Why?
| | Positive-Pressure Respiration | 2 | 2014 | 59 | 0.850 |
Why?
| | Respiration | 7 | 2019 | 100 | 0.840 |
Why?
| | Models, Anatomic | 7 | 2023 | 41 | 0.840 |
Why?
| | Status Asthmaticus | 1 | 2022 | 6 | 0.820 |
Why?
| | Catheterization | 1 | 2023 | 100 | 0.810 |
Why?
| | Outpatients | 1 | 2023 | 115 | 0.800 |
Why?
| | Body Height | 2 | 2021 | 65 | 0.750 |
Why?
| | Pressure | 2 | 2018 | 105 | 0.730 |
Why?
| | Noninvasive Ventilation | 2 | 2019 | 21 | 0.730 |
Why?
| | Hydrocarbons, Fluorinated | 2 | 2017 | 8 | 0.730 |
Why?
| | Surgical Mesh | 1 | 2020 | 17 | 0.710 |
Why?
| | Child, Preschool | 13 | 2021 | 3896 | 0.700 |
Why?
| | Curriculum | 1 | 2023 | 397 | 0.690 |
Why?
| | Infant | 12 | 2024 | 3584 | 0.670 |
Why?
| | Intubation, Intratracheal | 3 | 2023 | 120 | 0.650 |
Why?
| | Quality Improvement | 2 | 2018 | 206 | 0.600 |
Why?
| | Time Factors | 4 | 2017 | 2909 | 0.600 |
Why?
| | Lung Diseases | 3 | 2015 | 97 | 0.560 |
Why?
| | Patients' Rooms | 1 | 2016 | 4 | 0.560 |
Why?
| | Models, Theoretical | 5 | 2015 | 174 | 0.540 |
Why?
| | Equipment Failure Analysis | 2 | 2013 | 46 | 0.530 |
Why?
| | Larynx | 2 | 2013 | 30 | 0.530 |
Why?
| | Respiratory Mechanics | 2 | 2013 | 41 | 0.530 |
Why?
| | Nose | 2 | 2013 | 31 | 0.530 |
Why?
| | Time-to-Treatment | 1 | 2016 | 70 | 0.510 |
Why?
| | Patient Transfer | 1 | 2016 | 94 | 0.510 |
Why?
| | Insufflation | 1 | 2015 | 10 | 0.500 |
Why?
| | Technology Assessment, Biomedical | 1 | 2015 | 11 | 0.500 |
Why?
| | Family Relations | 1 | 2015 | 22 | 0.500 |
Why?
| | Airway Management | 1 | 2015 | 19 | 0.500 |
Why?
| | Neuromuscular Diseases | 1 | 2015 | 30 | 0.490 |
Why?
| | Delivery of Health Care | 1 | 2018 | 308 | 0.490 |
Why?
| | Cough | 1 | 2015 | 55 | 0.480 |
Why?
| | Respiratory Rate | 2 | 2015 | 7 | 0.470 |
Why?
| | Respiratory Dead Space | 2 | 2014 | 2 | 0.470 |
Why?
| | Life Style | 1 | 2015 | 140 | 0.470 |
Why?
| | Rural Population | 1 | 2018 | 551 | 0.430 |
Why?
| | Models, Biological | 5 | 2014 | 722 | 0.420 |
Why?
| | Male | 17 | 2022 | 25572 | 0.410 |
Why?
| | Emergency Service, Hospital | 1 | 2016 | 482 | 0.410 |
Why?
| | Filtration | 1 | 2012 | 24 | 0.400 |
Why?
| | Severe Acute Respiratory Syndrome | 1 | 2012 | 17 | 0.400 |
Why?
| | Telemedicine | 1 | 2018 | 467 | 0.380 |
Why?
| | Spectrophotometry | 3 | 2019 | 32 | 0.380 |
Why?
| | Female | 16 | 2022 | 26829 | 0.370 |
Why?
| | Adult | 8 | 2021 | 13486 | 0.370 |
Why?
| | Inhalation Spacers | 3 | 2016 | 6 | 0.340 |
Why?
| | Adolescent | 8 | 2021 | 6459 | 0.300 |
Why?
| | Cross-Over Studies | 2 | 2018 | 223 | 0.270 |
Why?
| | Adrenergic beta-Agonists | 1 | 2006 | 41 | 0.260 |
Why?
| | Respiratory Insufficiency | 2 | 2007 | 115 | 0.250 |
Why?
| | Bronchial Spasm | 1 | 2024 | 4 | 0.240 |
Why?
| | Educational Status | 1 | 2023 | 225 | 0.200 |
Why?
| | Suspensions | 1 | 2021 | 4 | 0.190 |
Why?
| | Pediatrics | 2 | 2015 | 280 | 0.180 |
Why?
| | Bronchiolitis | 1 | 2021 | 27 | 0.180 |
Why?
| | Electronic Health Records | 1 | 2023 | 208 | 0.180 |
Why?
| | Materials Testing | 2 | 2010 | 56 | 0.180 |
Why?
| | Budesonide | 1 | 2020 | 2 | 0.180 |
Why?
| | Tropanes | 1 | 2020 | 4 | 0.180 |
Why?
| | Anti-Asthmatic Agents | 1 | 2020 | 29 | 0.170 |
Why?
| | Percussion | 1 | 2019 | 1 | 0.170 |
Why?
| | Primary Health Care | 1 | 2023 | 363 | 0.170 |
Why?
| | Length of Stay | 1 | 2022 | 627 | 0.160 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 127 | 0.150 |
Why?
| | Oxygen | 1 | 2021 | 321 | 0.150 |
Why?
| | Infant, Newborn | 3 | 2015 | 2770 | 0.150 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 132 | 0.150 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 281 | 0.150 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 76 | 0.150 |
Why?
| | Procaterol | 1 | 2017 | 2 | 0.150 |
Why?
| | Decision Making | 2 | 2020 | 273 | 0.140 |
Why?
| | Community Health Services | 1 | 2018 | 101 | 0.140 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 170 | 0.140 |
Why?
| | Research Design | 1 | 2019 | 344 | 0.140 |
Why?
| | Quality Assurance, Health Care | 1 | 2018 | 149 | 0.140 |
Why?
| | Random Allocation | 1 | 2017 | 288 | 0.140 |
Why?
| | Coronavirus Infections | 1 | 2020 | 179 | 0.140 |
Why?
| | Face | 2 | 2015 | 58 | 0.140 |
Why?
| | Single-Blind Method | 1 | 2016 | 114 | 0.140 |
Why?
| | Health Communication | 1 | 2017 | 22 | 0.140 |
Why?
| | Models, Statistical | 1 | 2018 | 225 | 0.140 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 369 | 0.130 |
Why?
| | Compressed Air | 1 | 2016 | 2 | 0.130 |
Why?
| | United States | 3 | 2018 | 4898 | 0.130 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2016 | 326 | 0.130 |
Why?
| | Computer Simulation | 2 | 2013 | 281 | 0.130 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2015 | 17 | 0.130 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2015 | 24 | 0.120 |
Why?
| | Radiography | 2 | 2013 | 485 | 0.120 |
Why?
| | Administration, Intranasal | 1 | 2015 | 30 | 0.120 |
Why?
| | Transition to Adult Care | 1 | 2015 | 17 | 0.120 |
Why?
| | Radionuclide Imaging | 1 | 2014 | 116 | 0.110 |
Why?
| | Respiratory Function Tests | 1 | 2014 | 88 | 0.110 |
Why?
| | Nasal Sprays | 1 | 2013 | 3 | 0.110 |
Why?
| | Head Movements | 1 | 2013 | 6 | 0.110 |
Why?
| | Respiratory System | 1 | 2013 | 27 | 0.110 |
Why?
| | Comparative Effectiveness Research | 1 | 2013 | 44 | 0.110 |
Why?
| | Drug Monitoring | 1 | 2013 | 78 | 0.110 |
Why?
| | Head | 1 | 2013 | 70 | 0.110 |
Why?
| | Pharmaceutical Preparations | 1 | 2013 | 77 | 0.100 |
Why?
| | Retrospective Studies | 4 | 2021 | 6190 | 0.100 |
Why?
| | Disposable Equipment | 1 | 2010 | 5 | 0.090 |
Why?
| | Solutions | 1 | 2010 | 24 | 0.090 |
Why?
| | Technology, Pharmaceutical | 1 | 2010 | 4 | 0.090 |
Why?
| | Young Adult | 1 | 2020 | 4052 | 0.090 |
Why?
| | Treatment Outcome | 1 | 2019 | 5203 | 0.080 |
Why?
| | Prognosis | 1 | 2014 | 1963 | 0.080 |
Why?
| | Bronchoscopy | 1 | 2008 | 70 | 0.070 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2007 | 6 | 0.070 |
Why?
| | Aging | 1 | 2012 | 674 | 0.070 |
Why?
| | Cromolyn Sodium | 1 | 2006 | 1 | 0.070 |
Why?
| | Fluocinolone Acetonide | 1 | 2006 | 5 | 0.070 |
Why?
| | Tobramycin | 1 | 2006 | 16 | 0.070 |
Why?
| | Drug Combinations | 1 | 2006 | 126 | 0.060 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2007 | 290 | 0.060 |
Why?
| | Hemoptysis | 1 | 2002 | 5 | 0.050 |
Why?
| | Nutrition Disorders | 1 | 2002 | 14 | 0.050 |
Why?
| | Saline Solution, Hypertonic | 1 | 2022 | 14 | 0.050 |
Why?
| | Deoxyribonuclease I | 1 | 2022 | 34 | 0.050 |
Why?
| | Pneumothorax | 1 | 2002 | 21 | 0.050 |
Why?
| | Steroids | 1 | 2002 | 56 | 0.050 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2022 | 36 | 0.050 |
Why?
| | Liver Diseases | 1 | 2002 | 79 | 0.050 |
Why?
| | Diabetes Complications | 1 | 2002 | 118 | 0.050 |
Why?
| | Acute Disease | 1 | 2002 | 368 | 0.050 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2021 | 20 | 0.050 |
Why?
| | Middle Aged | 2 | 2013 | 12356 | 0.050 |
Why?
| | Odds Ratio | 1 | 2002 | 548 | 0.050 |
Why?
| | Nutritional Status | 1 | 2021 | 136 | 0.040 |
Why?
| | Sex Factors | 1 | 2002 | 700 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2006 | 744 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2002 | 1145 | 0.040 |
Why?
| | Societies, Medical | 1 | 2020 | 177 | 0.040 |
Why?
| | Age Factors | 1 | 2002 | 1096 | 0.040 |
Why?
| | Critical Care | 1 | 2021 | 215 | 0.040 |
Why?
| | Cohort Studies | 1 | 2002 | 1414 | 0.040 |
Why?
| | Self Efficacy | 1 | 2017 | 130 | 0.030 |
Why?
| | Pandemics | 1 | 2020 | 567 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2017 | 280 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 584 | 0.030 |
Why?
| | Risk Factors | 1 | 2002 | 3644 | 0.030 |
Why?
| | Numerical Analysis, Computer-Assisted | 1 | 2013 | 4 | 0.030 |
Why?
| | Rheology | 1 | 2013 | 7 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2015 | 235 | 0.030 |
Why?
| | Motion | 1 | 2013 | 19 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2015 | 184 | 0.030 |
Why?
| | Patient Care Team | 1 | 2015 | 258 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2015 | 284 | 0.030 |
Why?
| | Necrosis | 1 | 2007 | 175 | 0.020 |
Why?
|
|
Berlinski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|